IPS Patient Platform has been selected to support and gather patient insights from clinical trials - March 2022

IPS’s patient platform, PatientSelf, enables pharmaceutical companies to take a new approach to discovering patient outcomes during and on exiting clinical studies.

PatientSelf has been developed in collaboration with some of the world’s leading academic institutions to discover patient outcomes and experiences from phase II/III clinical trials and real-world evidence studies. The digital platform uses AI to identify previously missed outcomes and enables development of new metrics to measure and evaluate improvement experienced by patients in clinical studies.